Refining the Mantle Cell Lymphoma Paradigm: Impact of Novel Therapies on Current Practice

No abstract is available for this paper.

• Publication year

  2015

• Venue

  Clinical Cancer Research

• Publication date

  2015-06-09

• Fields of study

  Medicine

• Identifiers
  DOI 10.1158/1078-0432.CCR-15-0488PMID 26059189
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Newly diagnosed and relapsed mantle cell lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.

  2017cited by this paper
• Bortezomib-based therapy for newly diagnosed mantle-cell lymphoma.

  2015cited by this paper
• miR-18b overexpression identifies mantle cell lymphoma patients with poor outcome and improves the MIPI-B prognosticator.

  2015cited by this paper
• Bortezomib Maintenance (BM) Versus Consolidation (BC) Following Aggressive Immunochemotherapy and Autologous Stem Cell Transplant (ASCT) for Untreated Mantle Cell Lymphoma (MCL): CALGB (Alliance) 50403

  2015cited by this paper
• Addition of bortezomib to standard dose chop chemotherapy improves response and survival in relapsed mantle cell lymphoma

  2015cited by this paper
• Chemotherapy-refractory diffuse large B-cell lymphoma and indolent B-cell malignancies can be effectively treated with autologous T cells expressing an anti-CD19 chimeric antigen receptor.

  2015cited by this paper
• Randomized trial of bendamustine-rituximab or R-CHOP/R-CVP in first-line treatment of indolent NHL or MCL: the BRIGHT study.

  2014influential reference
• Phase 2 study of VcR-CVAD with maintenance rituximab for untreated mantle cell lymphoma : an Eastern Cooperative Oncology Group study ( E 1405 )

  2014cited by this paper
• Nordic MCL3 study: 90Y-ibritumomab-tiuxetan added to BEAM/C in non-CR patients before transplant in mantle cell lymphoma.

  2014cited by this paper
• A phase 1 study of the PI3Kδ inhibitor idelalisib in patients with relapsed/refractory mantle cell lymphoma (MCL).

  2014cited by this paper
• The EBMT/EMCL consensus project on the role of autologous and allogeneic stem cell transplantation in mantle cell lymphoma

  2014cited by this paper
• Use of statins and the risk of death in patients with prostate cancer.

  2014cited by this paper
• Mantle cell lymphoma epidemiology: a population-based study in France

  2014cited by this paper
• Newly diagnosed and relapsed mantle cell lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.

  2014cited by this paper
• Ofatumumab monotherapy in relapsed/refractory mantle cell lymphoma – a phase II trial

  2014cited by this paper
• Non-Hodgkin's lymphomas, version 4.2014.

  2014cited by this paper
• Is there a role for therapy response assessment with 2-[fluorine-18] fluoro-2-deoxy-d-glucose–positron emission tomography/computed tomography in mantle cell lymphoma?

  2014cited by this paper
• A phase I/II study of the pan Bcl-2 inhibitor obatoclax mesylate plus bortezomib for relapsed or refractory mantle cell lymphoma

  2014cited by this paper
• Phase I study of ABT-199 (GDC-0199) in patients with relapsed/refractory non-Hodgkin lymphoma: responses observed in diffuse large B-cell (DLBCL) and follicular lymphoma (FL) at higher cohort doses.

  2014cited by this paper
• Confirmation of the mantle-cell lymphoma International Prognostic Index in randomized trials of the European Mantle-Cell Lymphoma Network.

  2014cited by this paper
• Outcome and prognostic factors in patients with mantle-cell lymphoma relapsing after autologous stem-cell transplantation: a retrospective study of the European Group for Blood and Marrow Transplantation (EBMT).

  2014cited by this paper
• Frontline Therapy with the Ribvd Regimen Elicits High Clinical and Molecular Response Rates and Long PFS in Elderly Patients Mantle Cell Lymphoma (MCL); Final Results of a Prospective Phase II Trial By the Lysa Group

  2014cited by this paper
• Therapy of B Cell Malignancies with CD19-Specific Chimeric Antigen Receptor-Modified T Cells of Defined Subset Composition

  2014cited by this paper
• Newly diagnosed and relapsed follicular lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.

  2014cited by this paper
• MRD Eradication Should be the Therapeutic Goal in Mantle Cell Lymphoma and May Enable Tailored Treatment Approaches: Results of the Intergroup Trials of the European MCL Network

  2014cited by this paper
• Safety and activity of PD1 blockade by pidilizumab in combination with rituximab in patients with relapsed follicular lymphoma: a single group, open-label, phase 2 trial.

  2014cited by this paper
• Phase 2 study of VcR-CVAD with maintenance rituximab for untreated mantle cell lymphoma: an Eastern Cooperative Oncology Group study (E1405).

  2014cited by this paper
• Sustained Remission with the Combination Biologic Doublet of Lenalidomide Plus Rituximab As Initial Treatment for Mantle Cell Lymphoma: A Multi-Center Phase II Study Report

  2014cited by this paper
• Rituximab Maintenance Versus Wait and Watch after Four Courses of R-DHAP Followed By Autologous Stem Cell transplantation in Previously Untreated Young Patients with Mantle Cell Lymphoma: First Interim Analysis of the Phase III Prospective Lyma Trial, a Lysa Study

  2014cited by this paper
• Autologous stem cell transplantation in mantle cell lymphoma: a report from the SFGM-TC

  2014cited by this paper
• SOX11 and TP53 add prognostic information to MIPI in a homogenously treated cohort of mantle cell lymphoma – a Nordic Lymphoma Group study

  2014cited by this paper
• Diffuse Large B Cell Lymphoma (DLBCL) infiltrating T Cells Display an Activated and Exhausted Status and Are Inhibited By Ligands of Cosignaling Receptors Including PD-L1, PD-L2 and CD80 Expressed By Most DLBCL in Situ

  2014cited by this paper
• Real world data on primary treatment for mantle cell lymphoma: a Nordic Lymphoma Group observational study.

  2013cited by this paper
• Obinutuzumab (GA101) monotherapy in relapsed/refractory diffuse large b-cell lymphoma or mantle-cell lymphoma: results from the phase II GAUGUIN study.

  2013cited by this paper
• Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma.

  2013cited by this paper
• CHOP and DHAP plus rituximab followed by autologous stem cell transplantation in mantle cell lymphoma: a phase 2 study from the Groupe d'Etude des Lymphomes de l'Adulte.

  2013cited by this paper
• Landscape of somatic mutations and clonal evolution in mantle cell lymphoma

  2013cited by this paper
• Single-agent lenalidomide in patients with mantle-cell lymphoma who relapsed or progressed after or were refractory to bortezomib: phase II MCL-001 (EMERGE) study.

  2013influential reference
• A phase II multicenter trial of hyperCVAD MTX/Ara-C and rituximab in patients with previously untreated mantle cell lymphoma; SWOG 0213.

  2013cited by this paper
• Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial.

  2013cited by this paper
• Long-term follow-up of lenalidomide in relapsed/refractory mantle cell lymphoma: subset analysis of the NHL-003 study

  2013cited by this paper
• Combination of rituximab, bendamustine, and cytarabine for patients with mantle-cell non-Hodgkin lymphoma ineligible for intensive regimens or autologous transplantation.

  2013cited by this paper
• Association of pre-transplantation positron emission tomography/computed tomography and outcome in mantle cell lymphoma

  2013cited by this paper
• Allogeneic hematopoietic cell transplantation for chemotherapy-unresponsive mantle cell lymphoma: a cohort analysis from the center for international blood and marrow transplant research.

  2013cited by this paper
• Complete remission after treatment with single-agent ofatumumab in a patient with high-risk leukemic mantle-cell lymphoma.

  2013cited by this paper
• Non-nodal type of mantle cell lymphoma is a specific biological and clinical subgroup of the disease

  2012cited by this paper
• Molecular subsets of mantle cell lymphoma defined by the IGHV mutational status and SOX11 expression have distinct biologic and clinical features.

  2012cited by this paper
• Treatment of older patients with mantle-cell lymphoma.

  2012cited by this paper
• Comparative outcome of initial therapy for younger patients with mantle cell lymphoma: an analysis from the NCCN NHL Database.

  2012cited by this paper
• In situ mantle cell lymphoma: clinical implications of an incidental finding with indolent clinical behavior

  2012cited by this paper
• Detection of minimal residual disease following induction immunochemotherapy predicts progression free survival in mantle cell lymphoma: final results of CALGB 59909

  2012cited by this paper
• Post‐treatment (not interim) positron emission tomography‐computed tomography scan status is highly predictive of outcome in mantle cell lymphoma patients treated with R‐HyperCVAD

  2012cited by this paper
• Phase II study of rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone immunochemotherapy followed by yttrium-90-ibritumomab tiuxetan in untreated mantle-cell lymphoma: Eastern Cooperative Oncology Group Study E1499.

  2012cited by this paper
• Nordic MCL2 trial update: six‐year follow‐up after intensive immunochemotherapy for untreated mantle cell lymphoma followed by BEAM or BEAC + autologous stem‐cell support: still very long survival but late relapses do occur

  2012influential reference
• Lenalidomide in combination with rituximab for patients with relapsed or refractory mantle-cell lymphoma: a phase 1/2 clinical trial.

  2012cited by this paper
• Survival trends in mantle cell lymphoma in the United States over 16 years 1992–2007

  2012cited by this paper
• Prolonged immunochemotherapy with rituximab, cytarabine and fludarabine added to cyclophosphamide, doxorubicin, vincristine and prednisolone and followed by rituximab maintenance in untreated elderly patients with mantle cell lymphoma: a prospective study by the Finnish Lymphoma Group

  2012cited by this paper
• Treatment of older patients with mantle-cell lymphoma.

  2012influential reference
• Mantle cell lymphoma: biology, pathogenesis, and the molecular basis of treatment in the genomic era.

  2011cited by this paper
• Bortezomib plus CHOP-rituximab for previously untreated diffuse large B-cell lymphoma and mantle cell lymphoma.

  2011cited by this paper
• The combination of bendamustine, bortezomib, and rituximab for patients with relapsed/refractory indolent and mantle cell non-Hodgkin lymphoma.

  2011cited by this paper
• VcR‐CVAD induction chemotherapy followed by maintenance rituximab in mantle cell lymphoma: a Wisconsin Oncology Network study

  2011cited by this paper
• Mantle cell lymphoma: the promise of new treatment options.

  2011influential reference
• Navitoclax, a targeted high-affinity inhibitor of BCL-2, in lymphoid malignancies: a phase 1 dose-escalation study of safety, pharmacokinetics, pharmacodynamics, and antitumour activity.

  2010cited by this paper
• Ten‐year follow‐up after intense chemoimmunotherapy with Rituximab‐HyperCVAD alternating with Rituximab‐high dose methotrexate/cytarabine (R‐MA) and without stem cell transplantation in patients with untreated aggressive mantle cell lymphoma

  2010cited by this paper
• High rate and prolonged duration of complete remissions induced by rituximab, methotrexate, doxorubicin, cyclophosphamide, vincristine, ifosfamide, etoposide, cytarabine, and thalidomide (R-MACLO-IVAM-T), a modification of the National Cancer Institute 89-C-41 regimen, in patients with newly diagnos

  2010cited by this paper
• Genomic and gene expression profiling defines indolent forms of mantle cell lymphoma.

  2010cited by this paper
• Increasing the efficacy of CD20 antibody therapy through the engineering of a new type II anti-CD20 antibody with enhanced direct and immune effector cell-mediated B-cell cytotoxicity.

  2010cited by this paper
• Molecular remission is an independent predictor of clinical outcome in patients with mantle cell lymphoma after combined immunochemotherapy: a European MCL intergroup study.

  2010cited by this paper
• Lenalidomide oral monotherapy produces a high response rate in patients with relapsed or refractory mantle cell lymphoma

  2009cited by this paper
• Phase III study to evaluate temsirolimus compared with investigator's choice therapy for the treatment of relapsed or refractory mantle cell lymphoma.

  2009cited by this paper
• Immunochemotherapy and autologous stem-cell transplantation for untreated patients with mantle-cell lymphoma: CALGB 59909.

  2009cited by this paper
• Time to treatment does not influence overall survival in newly diagnosed mantle-cell lymphoma.

  2009influential reference
• Ofatumumab, a second-generation anti-CD20 monoclonal antibody, for the treatment of lymphoproliferative and autoimmune disorders.

  2009cited by this paper
• Bortezomib in patients with relapsed or refractory mantle cell lymphoma: updated time-to-event analyses of the multicenter phase 2 PINNACLE study.

  2009cited by this paper
• Mature results of the M. D. Anderson Cancer Center risk-adapted transplantation strategy in mantle cell lymphoma.

  2009cited by this paper
• Outcome of deferred initial therapy in mantle-cell lymphoma.

  2009cited by this paper
• Clinical Trials and Observations

  2008influential reference
• Ki-67 predicts outcome in advanced-stage mantle cell lymphoma patients treated with anti-CD20 immunochemotherapy: results from randomized trials of the European MCL Network and the German Low Grade Lymphoma Study Group.

  2008influential reference
• Long-term progression-free survival of mantle cell lymphoma after intensive front-line immunochemotherapy with in vivo-purged stem cell rescue: a nonrandomized phase 2 multicenter study by the Nordic Lymphoma Group.

  2008cited by this paper
• Multicenter phase II study of bortezomib in patients with relapsed or refractory mantle cell lymphoma.

  2006cited by this paper
• Mutation and genomic deletion status of ataxia telangiectasia mutated (ATM) and p53 confer specific gene expression profiles in mantle cell lymphoma

  2006cited by this paper
• A new prognostic index (MIPI) for patients with advanced-stage mantle cell lymphoma.

  2006cited by this paper
• High rate of durable remissions after treatment of newly diagnosed aggressive mantle-cell lymphoma with rituximab plus hyper-CVAD alternating with rituximab plus high-dose methotrexate and cytarabine.

  2005cited by this paper
• Bendamustine plus rituximab is effective and has a favorable toxicity profile in the treatment of mantle cell and low-grade non-Hodgkin's lymphoma.

  2005cited by this paper
• Rituximab maintenance following a rituximab containing chemotherapy significantly prolongs the duration of response in patients with relapsed follicular and mantle cell lymphomas: Results of a prospective randomized trial of the German Low Grade Lymphoma Study Group (GLSG)

  2005cited by this paper
• Immunochemotherapy with rituximab and cyclophosphamide, doxorubicin, vincristine, and prednisone significantly improves response and time to treatment failure, but not long-term outcome in patients with previously untreated mantle cell lymphoma: results of a prospective randomized trial of the Germa

  2005cited by this paper
• Millennium Pharmaceuticals

  2004cited by this paper
• Antitumor activity of rituximab plus thalidomide in patients with relapsed/refractory mantle cell lymphoma.

  2004cited by this paper
• Early consolidation by myeloablative radiochemotherapy followed by autologous stem cell transplantation in first remission significantly prolongs progression-free survival in mantle-cell lymphoma: results of a prospective randomized trial of the European MCL Network.

  2004cited by this paper
• The proliferation gene expression signature is a quantitative integrator of oncogenic events that predicts survival in mantle cell lymphoma.

  2003cited by this paper
• Rituximab and CHOP induction therapy for newly diagnosed mantle-cell lymphoma: molecular complete responses are not predictive of progression-free survival.

  2002cited by this paper
• New approach to classifying non-Hodgkin's lymphomas: clinical features of the major histologic subtypes. Non-Hodgkin's Lymphoma Classification Project.

  1998cited by this paper

• Tumor evolution and immune microenvironment dynamics in primary and relapsed mantle cell lymphoma

  2025cites this paper
• Superiority of ibrutinib plus bendamustine and rituximab in newly diagnosed patients with mantle‐cell lymphoma ineligible for intensive therapy: A network meta‐analysis

  2023cites this paper
• Nano-scale delivery systems for siRNA delivery in cancer therapy: New era of gene therapy empowered by nanotechnology.

  2023cites this paper
• Real‐world experience among patients with relapsed/refractory mantle cell lymphoma after Bruton tyrosine kinase inhibitor failure in Europe: The SCHOLAR‐2 retrospective chart review study

  2022cites this paper
• Combinatorial inhibition of BTK, PI3K-AKT and BRD4-MYC as a strategy for treatment of mantle cell lymphoma

  2022cites this paper
• Recent advances in siRNA delivery mediated by lipid-based nanoparticles

  2020cites this paper
• Prospective subgroup analyses of the randomized MCL-002 (SPRINT) study: lenalidomide versus investigator's choice in relapsed or refractory mantle cell lymphoma versus therapy in

  2020cites this paper
• Treatment of Lymphoid and Myeloid Malignancies by Immunomodulatory Drugs.

  2019cites this paper
• Frontline bortezomib, rituximab, cyclophosphamide, doxorubicin, and prednisone (VR-CAP) versus rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) in transplantation-ineligible patients with newly diagnosed mantle cell lymphoma: final overall survival results of a randomis

  2018cites this paper
• Lipid nanoparticle siRNA cocktails for the treatment of mantle cell lymphoma

  2018influential citation
• Treatment for patients with relapsed/refractory mantle cell lymphoma: European-based recommendations

  2018cites this paper
• PQR309 Is a Novel Dual PI3K/mTOR Inhibitor with Preclinical Antitumor Activity in Lymphomas as a Single Agent and in Combination Therapy

  2017cites this paper
• Observational study of lenalidomide in patients with mantle cell lymphoma who relapsed/progressed after or were refractory/intolerant to ibrutinib (MCL-004)

  2017cites this paper
• Prospective subgroup analyses of the randomized MCL‐002 (SPRINT) study: lenalidomide versus investigator's choice in relapsed or refractory mantle cell lymphoma

  2017influential citation
• Paclitaxel synergizes with exposure time adjusted CD22-targeting immunotoxins against B-cell malignancies

  2017cites this paper
• Autologous Stem Cell Transplant: Still the Standard for Fit Patients With Mantle Cell Lymphoma

  2017influential citation
• Mantle Cell Lymphoma: Contemporary Diagnostic and Treatment Perspectives in the Age of Personalized Medicine.

  2017cites this paper
• Advances in the diagnosis and control of lymphomas.

  2016cites this paper
• Late relapsing mantle cell lymphoma showing preserved sensitivity to single-agent lenalidomide

  2016cites this paper
• Impressive and durable response in a case of multiple relapsed mantle cell lymphoma treated with bortezomib and rituximab

  2016cites this paper
• Protein Arginine Methyltransferase 5 as a Driver of Lymphomagenesis

  2016cites this paper
• Phospholipid scramblase 1 as a critical node at the crossroad between autophagy and apoptosis in mantle cell lymphoma

  2016cites this paper
• Bortezomib for the treatment of mantle cell lymphoma: an update

  2016influential citation
• Novel Nanoscale Delivery Particles Encapsulated with Anticancer Drugs, All-trans Retinoic Acid or Curcumin, Enhance Apoptosis in Lymphoma Cells Predominantly Expressing CD20 Antigen.

  2015cites this paper